All In Biotech

Drug Trial Radar · NCT06032546

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Budigalimab and/or ABBV-382 in People Living With HIV on Stable Antiretroviral Therapy Undergoing Analytical Treatment Interruption

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 163 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

163

Actual

Start

Oct 12, 2023

Primary completion

Sep 22, 2025

Study completion Sep 22, 2025

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Sep 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic disease requiring lifelong therapy. The purpose of this study is to assess change in disease activity, adverse events, tolerability, and how the drug moves through the body. Budigalimab and ABBV-382 are investigational drugs being developed for the treatment of HIV disease. In Part 1, participants are placed in 1 of 5 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 7 chance that participants will be assigned to placebo (A placebo is not a drug and it is not expected to have any chemical effects on your body and it is not designed to treat any disease or illness). In Part 2, eligible participants will be placed in an open-label arm to receive Budigalimab. Approximately 160 adult participants living with HIV disease on stable antiretroviral therapy (ART) willing to undergo Analytical Treatment Interruption (ATI) will be enrolled at approximately 90 sites worldwide. In Part 1, participants will receive 4 doses of intravenous (IV) budigalimab or placebo combined with 3 doses of IV ABBV-382 or placebo for an 8 week dosing period. In Part 2, participants will receive 4 doses of open-label subcutaneous (SC) Budigalimab for a 6 week dosing period. Participants need to be stable on antiretroviral therapy to participate in the study. If participant qualifies to the study, on the day they receive the first injection, participants will be asked to stop antiretroviral medications (also referred to as analytical treatment interruption or ATI) for 112 weeks or until meeting specific criteria to restart antiretroviral medications. Participants will undergo a closely monitored ART interruption. Protocol-defined ART restart criteria includes participant's request. Participants will be followed for up to approximately 112 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. There will be an option for virtual or home health visits for some of the follow-up visits. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Human Immuno-deficiency Virus (HIV) Disease

Interventions

  • BudigalimabDrug

    Intravenous (IV) Infusion

  • Placebo for BudigalimabDrug

    IV Infusion

  • ABBV-382Drug

    IV Infusion

  • Placebo for ABBV-382Drug

    IV Infusion

  • BudigalimabDrug

    Subcutaneous (SC) Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Viral Control Without Antiretroviral Therapy (ART) RestartTime frame: Week 24
  2. Number of Participants With Adverse Events (AEs)Time frame: Up to approximately Week 112

Locations

80 sites in 13 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham, 1917 Research Clinic /ID# 257549

    Birmingham, Alabama

  • Franco Felizarta, Md /Id# 256927

    Bakersfield, California

  • AHF Research Center /ID# 257025

    Beverly Hills, California

  • Long Beach Education and Research Consultants /ID# 257552

    Long Beach, California

  • AHF Healthcare Center- Hollywood /ID# 257026

    Los Angeles, California

  • Los Angeles LGBT Center /ID# 258407

    Los Angeles, California

  • Ruane Clinical Research Group /ID# 256932

    Los Angeles, California

  • Palmtree Clinical Research Inc. /Id# 258409

    Palm Springs, California

  • Optimus Medical /ID# 257182

    San Francisco, California

  • Quest Clinical Research /ID# 256928

    San Francisco, California

  • Washington Health Institute /ID# 259336

    Washington D.C., District of Columbia

  • Midland Florida Clinical Research Center /ID# 257101

    DeLand, Florida

  • Ahf Healthcare Center - Northpoint /ID# 256934

    Fort Lauderdale, Florida

  • Midway Immunology and Research Center /ID# 256930

    Ft. Pierce, Florida

  • Advanced Pharma CR, LLC /ID# 259335

    Miami, Florida

  • Orlando Immunology Center /ID# 256931

    Orlando, Florida

  • Bliss Health /ID# 257827

    Orlando, Florida

  • Baycare Medical Group - Tampa /ID# 256953

    Tampa, Florida

  • The Pierone Research Institute /ID# 257022

    Vero Beach, Florida

  • Triple O Research Institute /ID# 256929

    West Palm Beach, Florida

  • Winship At Emory University Hospital Midtown /ID# 258410

    Atlanta, Georgia

  • Metro Infectious Disease Consultants /ID# 256955

    Decatur, Georgia

  • Howard Brown Health Center /ID# 257485

    Chicago, Illinois

  • Claudia T. Martorell MD LLC dba The Research Institute /ID# 259155

    Springfield, Massachusetts

  • KC CARE Health Center - Midtown South /ID# 257178

    Kansas City, Missouri

  • Las Vegas Research Center /ID# 257619

    Las Vegas, Nevada

  • Cooper University Health Care - Camden /ID# 258133

    Camden, New Jersey

  • Saint Michael's Medical Center /ID# 258802

    Newark, New Jersey

  • South Jersey Infectious Disease /ID# 257840

    Somers Point, New Jersey

  • The University of New Mexico /ID# 257533

    Albuquerque, New Mexico

  • Suny Upstate University Hospital Community Campus /ID# 257847

    Syracuse, New York

  • Jacobi Medical Center /ID# 257849

    The Bronx, New York

  • Montefiore Medical Center /ID# 257792

    The Bronx, New York

  • East Carolina University - Brody School of Medicine /ID# 257544

    Greenville, North Carolina

  • Atrium Health Wake Forest Baptist Medical Center /ID# 257542

    Winston-Salem, North Carolina

  • Central Texas Clinical Research /ID# 256920

    Austin, Texas

  • Prism Health North Texas - Oak Cliff Health Center /ID# 256933

    Dallas, Texas

  • North Texas Infectious Diseases Consultants, P.A /ID# 257592

    Dallas, Texas

  • University of Texas Southwestern Medical Center /ID# 257551

    Dallas, Texas

  • Texas Center for Infectious Disease Associates /ID# 257183

    Fort Worth, Texas

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.